Betta Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Betta Pharmaceuticals has a total shareholder equity of CN¥5.6B and total debt of CN¥2.5B, which brings its debt-to-equity ratio to 44.2%. Its total assets and total liabilities are CN¥9.3B and CN¥3.7B respectively. Betta Pharmaceuticals's EBIT is CN¥365.3M making its interest coverage ratio 9.9. It has cash and short-term investments of CN¥554.6M.
Key information
44.2%
Debt to equity ratio
CN¥2.48b
Debt
Interest coverage ratio | 9.9x |
Cash | CN¥554.56m |
Equity | CN¥5.61b |
Total liabilities | CN¥3.71b |
Total assets | CN¥9.33b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 300558's short term assets (CN¥1.3B) do not cover its short term liabilities (CN¥1.4B).
Long Term Liabilities: 300558's short term assets (CN¥1.3B) do not cover its long term liabilities (CN¥2.3B).
Debt to Equity History and Analysis
Debt Level: 300558's net debt to equity ratio (34.3%) is considered satisfactory.
Reducing Debt: 300558's debt to equity ratio has increased from 30.1% to 44.2% over the past 5 years.
Debt Coverage: 300558's debt is well covered by operating cash flow (41.3%).
Interest Coverage: 300558's interest payments on its debt are well covered by EBIT (9.9x coverage).